UPDATE: Stifel Starts Inventiva SA (IVA) at Buy

August 4, 2020 4:17 AM EDT
Get Alerts IVA Hot Sheet
Price: $14.13 +1.65%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 8 | New: 24
Trade Now! 
Join SI Premium – FREE
(Updated - August 4, 2020 5:01 AM EDT)

(updating comment)

Stifel analyst Derek Archila initiates coverage on Inventiva SA (NASDAQ: IVA) with a Buy rating and a price target of $18.00.

The analyst comments "We are initiating coverage on IVA shares with a Buy rating and $18 price target. Our thesis is predicated on: (1) lanifibranor's highly impressive Phase 2 results in NASH where it demonstrated a stat sig benefit on both fibrosis improvement and NASH resolution in 24 weeks; (2) its highly encouraging results on lipid and T2D biomarkers which indicate lanifibranor is having a positive effect on the metabolic disease underlying NASH; and (3) lanifibranor was generally found to be safe and tolerable, though we expect this to be a key debate among investors. While NASH development timelines are long and recent events in the NASH category (i.e. ICPT's complete response letter) have made investors more cautious, we think current levels offer long-term investors a nice entry point as IVA trades at a meaningful discount to its peers at the same stage of clinical development and some with less impressive data."

For an analyst ratings summary and ratings history on Inventiva SA click here. For more ratings news on Inventiva SA click here.

Shares of Inventiva SA closed at $10.24 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Stifel